Orexigen Therapeutics Inc.'s (Nasdaq: OREX) obesity treatment Contrave reduced the risk of heart disease by almost half. The stock price leaped $2.79 to $8.58.
Orexigen's Contrave lowers heart disease risk
March 03, 2015 at 12:33 PM EST
Orexigen's Contrave lowers heart disease riskMarch 03, 2015 at 12:33 PM EST
Orexigen Therapeutics Inc.'s (Nasdaq: OREX) obesity treatment Contrave reduced the risk of heart disease by almost half. The stock price leaped $2.79 to $8.58.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|